Oncologic “Threshold Of Credibility” Paradigm Being Explored At FDA
Executive Summary
Oncologic approval could be based on surpassing a "threshold of credibility" rather than demonstrating statistical benefit under a new review approach being explored at FDA
You may also be interested in...
Accelerated Approval Requests Based On Low Efficacy Frustrate FDA
FDA appears to be increasingly frustrated with sponsors who seek accelerated approval based upon the lowest possible efficacy standard
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials